China Traditional Chinese Medicine Holdings closed at HK$1.39 on the day of its half year 2026 results, after a flat week and a weak three month run. The stock has been trading as if the story is broken. The headline from these numbers is not revenue in isolation. It is the deepening loss that keeps pressure on the entire earnings path.
H1 2026 net income from ongoing operations remained in the red at several hundred million renminbi and basic earnings per share stayed negative. That loss profile sits in contrast with multi year forecasts that indicate a potential move back into profitability within three years.
Is China Traditional Chinese Medicine Holdings a rare 73.4% discount opportunity, or is it simply priced for its deepening losses and slow revenue outlook? See how SEHK:570 screens on valuation, margins and peer multiples in the valuation analysis for China Traditional Chinese Medicine Holdings
H1 2026 Earnings Summary
- Total Revenue, H1 2026 vs. H1 2025: ¥5,438.498m vs. ¥7,463.383m (a revenue decline of 27.1%)
- Net Income from Ongoing Operations, H1 2026 vs. H1 2025: loss of ¥776.297m vs. loss of ¥107.918m (the loss widened by 619.7%)
- Basic EPS, H1 2026 vs. H1 2025: loss of ¥0.1542 per share vs. loss of ¥0.02143 per share (the per share loss widened by 619.7%)
- Trailing Twelve Month Net Income from Ongoing Operations, H1 2026 vs. H1 2025: loss of ¥1,010.449m vs. loss of ¥264.83m (the trailing loss increased by 281.5%)
Prefer clear charts instead of another wall of earnings tables and loss figures? See China Traditional Chinese Medicine Holdings' full valuation picture in an easy visual format in the company report for China Traditional Chinese Medicine Holdings.
China Traditional Chinese Medicine bullish signals under pressure
For a bullish view on China Traditional Chinese Medicine Holdings to hold, investors would usually want revenue stability and a path toward smaller losses. The latest half year shows revenue of ¥5,438.498m compared with ¥7,463.383m a year earlier, while losses from ongoing operations and basic EPS both moved further into the red. That combination of weaker top line and larger loss makes it harder to lean on the integrated TCM platform story as a near term support for a positive thesis.
Bearish concerns reinforced by deepening loss profile
The recent numbers give bears plenty to point to. Revenue declined by 27.1% year on year and the loss from ongoing operations widened sharply, both in the half year and on a trailing twelve month basis, now at ¥1,010.449m. Basic EPS also moved further into loss territory. The share price has fallen around 11% over three months and remains weak over 30 days. Taken together, the business results and recent trading performance align closely with a cautious or outright bearish stance on China Traditional Chinese Medicine Holdings.
Compare China Traditional Chinese Medicine Holdings' deepening losses with how the market is pricing its recovery risk. See the consensus price target analysis for China Traditional Chinese Medicine Holdings to check whether analysts think SEHK:570 is mispriced after these results.Take Control Of Your Next Move
If the widening losses and revenue pressure at China Traditional Chinese Medicine Holdings have your attention, register for free with Simply Wall St and add it to a Watchlist to track how the share price compares with fair value and watch for a better entry point. After you build a position, use the Portfolio Command Center to cut through noise and focus on the most important developments that could affect your holdings. For a longer term view, join the Community to see how other investors are thinking about risks and potential catalysts. This way you can spot key turning points early and stay ahead of the wider market.
Seeking Alternatives Beyond China Traditional Chinese Medicine
Fresh ideas move first and slow movers get caught chasing momentum. Scan these under the radar stocks while the data is still sharp and before prices start flying. Act now.
- Spot potential breakout balance sheets early by scanning the curated list of solid balance sheet and fundamentals stocks (426 results) while these companies are still under the radar for now.
- Ride structural power grid upgrades with hand picked businesses in the 38 power grid technology and infrastructure stocks before attention floods in and the best entry points start dropping away.
- Target cash generating AI opportunities by checking the filtered 73 profitable AI stocks that aren't just burning cash before the crowd chases the next wave of headlines. Get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com